Renovacor, Inc. (RCOR)
| Market Cap | 136.10M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.62M |
| Shares Out | 1.94M |
| EPS (ttm) | -4.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,596 |
| Open | 8.53 |
| Previous Close | 8.06 |
| Day's Range | 7.95 - 8.53 |
| 52-Week Range | 7.58 - 11.12 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About RCOR
Renovacor, Inc., an early-stage biotechnology company, engages in developing a pipeline of adeno-associated virus (AAV) based gene therapies for Bcl2-associated athanogene 3 (BAG3) associated diseases. Its lead program is recombinant AAV-based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the BAG3 gene; and REN-001, an AAV9-based gene therapy to treat BAG3-associated DCM. The company was incorporated in 2013 and is based in Greenwich, Connecticut.
Financial Performance
Financial StatementsNews
Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on...
PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. Closes its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange.
Chardan Healthcare Acquisition 2 Corp. Announces Stockholder Approval Of Business Combination With Renovacor, Inc.
NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ("CHAQ"), a special purpose acquisition company sponsored by Chardan Capital Markets ("Chardan"), today announ...
Chardan Healthcare Acquisition 2 Corp. Announces Renovacor's Appointment of Matt Killeen, Ph.D., as Chief Scientific ...
NEW YORK, Aug. 25, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor"), an early–stage biotechnology company developing adeno-associated virus (AAV)–based gene therapies for devastating cardiovascular an...
Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality A...
Dr. Zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapy Dr. Zhang has over 20 years of experience in regulatory affairs, wi...
Renovacor Announces the Appointments of Joan Lau, Ph.D., and Gregory F.
Appointments to be effective upon closing of the previously announced merger between Renovacor and Chardan Healthcare Acquisition 2 Corp. Appointments to be effective upon closing of the previously anno...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Chardan Healthcare Acquisition 2 Corp. - ...
NEW YORK, March 27, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class A...
Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp.
PHILADELPHIA and NEW YORK, March 23, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor" or the "Company"), an early-stage biotechnology company developing AAV-based gene therapies for devastating cardiov...